Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Carmat    ALCAR   FR0010907956

CARMAT

(ALCAR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
20.35(c) 20.7(c) 20.9(c) 20.45(c) 20.45(c) Last
5 893 12 104 5 496 4 684 4 405 Volume
-1.45% +1.72% +0.97% -2.15% 0.00% Change
More quotes
Financials (EUR)
Sales 2019 0,23 M
EBIT 2019 -44,8 M
Net income 2019 -44,6 M
Finance 2019 21,0 M
Yield 2019 -
Sales 2020 2,50 M
EBIT 2020 -45,1 M
Net income 2020 -44,4 M
Debt 2020 30,8 M
Yield 2020 -
P/E ratio 2019 -5,00x
P/E ratio 2020 -5,17x
EV / Sales2019 1 021x
EV / Sales2020 115x
Capitalization 257 M
More Financials
Company
Carmat specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all... 
More about the company
Surperformance© ratings of Carmat
Trading Rating : Investor Rating : -
More Ratings
Latest news on CARMAT
02/17CARMAT : Confirms the Submission of a “forfait Innovation” Dossier i..
BU
02/12CARMAT : Reports Its 2019 Annual Results and Confirms Its 2020 Objectives
BU
02/12CARMAT : Annual results
CO
02/05CARMAT : Announces FDA Full Approval to Initiate US Clinical Feasibility Study o..
BU
01/07CARMAT : 2020 Financial Calendar
PU
01/07CARMAT : 2020 Financial Calendar
BU
01/07CARMAT : Provisional calendar
CO
2019CARMAT : Resumes Enrollment in the PIVOTAL Study in the Czech Republic With Its ..
BU
2019CARMAT : Granted Authorization to Resume the PIVOTAL Study in Kazakhstan
BU
2019CARMAT : Appoints Alexandre Eleonore as Director of Manufacturing
BU
2019CARMAT : granted authorization to resume the PIVOTAL study in the Czech Republic
BU
2019CARMAT : Invited to Present at the Jefferies London Healthcare Conference
BU
2019CARMAT : The Feedback After 6 Years and 8 Months of Cumulative Support Shows a C..
BU
2019CARMAT : Invited to Present at the Ladenburg Thalmann Healthcare Conference in N..
BU
2019CARMAT : announces the success of its €60 million Reserved Offering for speciali..
BU
More news
News in other languages on CARMAT
02/18EN DIRECT DES MARCHES : Alstom, Société Générale, Orchestra, Apple, HSBC, Ama..
02/18STOCK MARKET PARIS : Le coronavirus rattrape Apple
02/18STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
02/18Les valeurs à suivre mardi 18 février 2020 à Paris -
02/18CARMAT : son coeur est éligible, avec observations, pour l’initiation d’une étud..
More news
Analyst Recommendations on CARMAT
More recommendations
Sector news : Medical Devices & Implants
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/20FISHER & PAYKEL HEALTHCARE : F&P Healthcare Raises Fiscal Year Earnings, Revenue..
DJ
02/20SMITH & NEPHEW : +Nephew forecasts sales growth after best year since 2010
RE
02/18MEDTRONIC : Raises 2020 Guidance, Sets 4Q Outlook
DJ
02/18MEDTRONIC : 3Q Profit, Sales Rise
DJ
More sector news : Medical Devices & Implants
Chart CARMAT
Duration : Period :
Carmat Technical Analysis Chart | ALCAR | FR0010907956 | MarketScreener
Technical analysis trends CARMAT
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 23,45  €
Last Close Price 20,45  €
Spread / Highest target 17,4%
Spread / Average Target 14,7%
Spread / Lowest Target 12,0%
EPS Revisions
Managers
NameTitle
Stéphane Piat Chief Executive Officer & Director
Jean-Pierre Garnier Chairman
Pascale d'Arbonneau Chief Financial & Administrative Officer
Marc Grimmé Director-Research & Development
Piet Jansen Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CARMAT6.07%280
STRYKER CORPORATION6.84%84 017
SMITH & NEPHEW PLC4.99%21 791
WRIGHT MEDICAL GROUP N.V.-0.23%3 915
GLAUKOS CORPORATION17.44%2 771
INSPIRE MEDICAL SYSTEMS, INC.9.49%1 901